Pemetrexed for Recurrent Primary Central Nervous System Lymphoma in the Elderly: Results of a Retrospective Study

Overview

Journal J Healthc Eng

Specialty Biomedical Engineering

Date 2022 Apr 8

PMID 35392141

Authors

Jing Xiao

Shishu Wang

Bing Xu

Lisha Yu

Yan Han

Affiliations

Soon will be listed here.

Abstract

Aim: Primary central nervous system lymphoma (PCNSL) is an aggressive, destructive, and rapidly progressive malignant brain tumor. Although aggressive therapies were studied trying to increase the median survival of PCNSL, the high relapse rate of PCNSL is still a big problem for the oncology medicine. A retrospective study was made to evaluate the efficacy and safety of pemetrexed in the treatment of patients with recurrent PCNSL.

Methods: Twenty-three confirmed recurrent PCNSL patients were selected during April 2012 and August 2016. Dexamethasone, B, and folic acid were used to produce the toxicity related to pemetrexed. The patients were intravenously given pemetrexed (900 mg/m) every three weeks for 6 weeks.

Results: After the treatment, 7 patients were in complete remission, 6 patients in partial remission, 4 patients in stable condition, and 6 patients in progression. There were 56.5% and 73.9% in the overall response rate and the disease control rate, respectively. The median overall survival (OS) was 6.6 months (95% CI, 4.6-8.6).

Conclusion: This study has been the first time to evaluate the safety and effectiveness of pemetrexed on elderly recurrent PCNSL patients. Results demonstrate that using high-dose pemetrexed might be a feasible and effective treatment for recurrent PCNSL in the elderly, and clinical trials should be conducted to further confirm it.

Citing Articles

Retracted: Pemetrexed for Recurrent Primary Central Nervous System Lymphoma in the Elderly: Results of a Retrospective Study.

Healthcare Engineering J J Healthc Eng. 2023; 2023:9847489.

PMID: 37771988 PMC: 10533307. DOI: 10.1155/2023/9847489.

References

Dietrich J, Versmee L, Drappatz J, Eichler A, Nayak L, Norden A . Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial. Oncologist. 2020; 25(9):747-e1273. PMC: 7485351. DOI: 10.1634/theoncologist.2020-0489. View

Ferreri A, Reni M, Foppoli M, Martelli M, Pangalis G, Frezzato M . High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009; 374(9700):1512-20. DOI: 10.1016/S0140-6736(09)61416-1. View

Nelson D, Martz K, Bonner H, Nelson J, NEWALL J, KERMAN H . Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992; 23(1):9-17. DOI: 10.1016/0360-3016(92)90538-s. View

Ng S, Rosenthal M, Ashley D, Cher L . High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro Oncol. 2001; 2(1):40-4. PMC: 1920699. DOI: 10.1093/neuonc/2.1.40. View

Zhu J, Gerstner E, Engler D, Mrugala M, Nugent W, Nierenberg K . High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2008; 11(2):211-5. PMC: 2718993. DOI: 10.1215/15228517-2008-067. View

Batchelor T, Carson K, ONeill A, Grossman S, Alavi J, New P . Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003; 21(6):1044-9. DOI: 10.1200/JCO.2003.03.036. View

Zhang J, Lee E, Nayak L, Doherty L, Kesari S, Muzikansky A . Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J Neurooncol. 2013; 115(1):71-7. DOI: 10.1007/s11060-013-1196-1. View

Han S, Wang M, Liu B, Yu J . Pemetrexed for primary central nervous system lymphoma in the elderly. Clin Transl Oncol. 2015; 18(2):138-43. DOI: 10.1007/s12094-015-1345-4. View

Raizer J, Rademaker A, Evens A, Rice L, Schwartz M, Chandler J . Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer. 2011; 118(15):3743-8. DOI: 10.1002/cncr.26709. View

10.

Enting R, Demopoulos A, DeAngelis L, Abrey L . Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004; 63(5):901-3. DOI: 10.1212/01.wnl.0000137050.43114.42. View

11.

Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M . High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010; 11(11):1036-47. DOI: 10.1016/S1470-2045(10)70229-1. View

12.

Abrey L . Primary central nervous system lymphoma. Curr Opin Neurol. 2009; 22(6):675-80. DOI: 10.1097/WCO.0b013e328332533b. View

13.

Voloschin A, Betensky R, Wen P, Hochberg F, Batchelor T . Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol. 2007; 86(2):211-5. DOI: 10.1007/s11060-007-9464-6. View

14.

Sun Y, Wang Y, Han S, Xing B, Li H, Zhu Y . Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: a prospective study. Onco Targets Ther. 2017; 10:2595-2600. PMC: 5440074. DOI: 10.2147/OTT.S134684. View

15.

Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M . Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007; 96(6):864-7. PMC: 2360092. DOI: 10.1038/sj.bjc.6603660. View

16.

Plotkin S, Betensky R, Hochberg F, Grossman S, Lesser G, Nabors L . Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004; 10(17):5643-6. DOI: 10.1158/1078-0432.CCR-04-0159. View

17.

Abrey L, Yahalom J, DeAngelis L . Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000; 18(17):3144-50. DOI: 10.1200/JCO.2000.18.17.3144. View

18.

Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L . Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006; 80(2):159-65. DOI: 10.1007/s11060-006-9165-6. View

19.

DeAngelis L, Yahalom J, Thaler H, Kher U . Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992; 10(4):635-43. DOI: 10.1200/JCO.1992.10.4.635. View

20.

Illerhaus G, Marks R, Muller F, Ihorst G, Feuerhake F, Deckert M . High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2008; 20(2):319-25. DOI: 10.1093/annonc/mdn628. View